abstract |
The present invention relates to a combination of two antibody molecules that bind to human DR5 antigen and their use in treating cancer. In particular, the present invention relates to dosage regimens for such anti-DR5 antibodies comprising administering to subject weekly dosages followed by biweekly dosages, or one or two priming dosage(s) followed by biweekly dosages. |